IL5RA and asthma: The total annual exacerbation events (defined as the sum of courses of oral corticosteroid and antibiotics, sick leaves, hospitalisations and emergency room visits because of asthma during the last 12 months) were significantly reduced in the anti-IL5/IL5R group from 7.6/year to 3.2/year (p < 0.05).